https://orcid.org/0000-0001-5982-8855
-
Views
-
Cite
Cite
Henry Maia Peixoto, Gustavo Adolfo Sierra Romero, Wildo Navegantes de Araújo, Maria Regina Fernandes de Oliveira, Guillain–Barré syndrome associated with Zika virus infection in Brazil: a cost-of-illness study, Transactions of The Royal Society of Tropical Medicine and Hygiene, Volume 113, Issue 5, May 2019, Pages 252–258, https://doi.org/10.1093/trstmh/trz010
Close - Share Icon Share
Abstract
Guillain–Barré syndrome (GBS) is a serious, acute paralytic neuropathy of autoimmune aetiology, usually associated with a previous infection. The current study aims to estimate the costs of GBS associated with Zika virus (ZIKV) infection in Brazil.
A cost-of-illness study was conducted from the perspective of the Brazilian public health system (Sistema Único de Saúde [SUS]) and Brazilian society for the year 2016. Direct and indirect costs were estimated by a mixed macrocosting and microcosting approach.
The total cost of ZIKV-associated GBS in Brazil was US$11 997 225.85, consisting of the costs of symptomatic ZIKV infection before onset of GBS (direct costs US$2011.51, indirect costs US$19 780.53) and the costs that followed development of GBS (direct costs US$4 722 980.89, indirect costs US$7 252 452.92). The cost of treatment with human immunoglobulin (US$3 263 210.50) and the cost of productivity losses associated with potential years of working life lost due to early mortality (US$4 398 551.72) were particularly noteworthy.
These findings suggest that ZIKV-associated GBS is costly to Brazil, especially due to productivity losses and hospitalization. This highlights the importance of investing in the prevention of ZIKV infection and in the care of patients with GBS.
Comments